Evaluating Survival, Long-Term Use of Nirogacestat in Desmoid Tumors
Nam Quoc Bui, MD, discusses survival, symptom control, and ovarian toxicity in the DeFi trial of nirogacestat in patients with desmoid tumors.
Related Articles
Improving Clinical Trials Through Inclusion, Access, and Engagement
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss potential strategies that teams can implement to ensure clinical trials are more representative…
Healio Disruptive Innovators Awards 2024
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Durvalumab Plus Chemotherapy Boosts EFS in Gastric/GEJ Cancer
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard care in this patient population.
Choosing Itacitinib for GVHD Prophylaxis: Insights From Popat
Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.
Ide-cel in Multiple Myeloma Post-Transplant: Insights From Garfall
Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
Acral Melanoma Survivor Warns: Know What to Look For
Dorothy was shocked when diagnosed with acral melanoma, a rare, dangerous skin cancer. Now, she wants to educate people on what to look for.
Cutting Delays in Cancer Care With Centralized Prior Authorizations
Andrea Ledford, PharmD, MBA, BCOP, BCSCP, FASHP, FHOPA, discussed a comprehensive pharmacy program presented at the 2025 ACCC Annual Meeting & Cancer Center Business Summit.
FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL
The FDA approved brentuximab vedotin plus lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma.
